Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Abbvie Inc’s stock clocked out at $184.85, down -2.33% from its previous closing price of $189.26. In other words, the price has decreased by -$2.33 from its previous closing price. On the day, 4.95 million shares were traded. ABBV stock price reached its highest trading level at $189.9 during the session, while it also had its lowest trading level at $184.63.
Ratios:
To gain a deeper understanding of ABBV’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 63.08 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 21.22. For the most recent quarter (mrq), Quick Ratio is recorded 0.64 and its Current Ratio is at 0.76. In the meantime, Its Debt-to-Equity ratio is 49.22 whereas as Long-Term Debt/Eq ratio is at 45.44.
On April 22, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $210.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 31 ’25 when Stewart Jeffrey Ryan sold 58,832 shares for $210.08 per share. The transaction valued at 12,359,504 led to the insider holds 53,234 shares of the business.
Stewart Jeffrey Ryan bought 58,832 shares of ABBV for $12,359,897 on Mar 31 ’25. On Mar 14 ’25, another insider, Reents Scott T, who serves as the EVP, CHIEF FINANCIAL OFFICER of the company, sold 17,644 shares for $212.34 each. As a result, the insider received 3,746,527 and left with 11,577 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABBV now has a Market Capitalization of 326519062528 and an Enterprise Value of 392769732608. As of this moment, Abbvie’s Price-to-Earnings (P/E) ratio for their current fiscal year is 78.82, and their Forward P/E ratio for the next fiscal year is 13.18. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.14. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.69 while its Price-to-Book (P/B) ratio in mrq is 229.93. Its current Enterprise Value per Revenue stands at 6.847 whereas that against EBITDA is 14.352.
Stock Price History:
The Beta on a monthly basis for ABBV is 0.50, which has changed by 0.090144634 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, ABBV has reached a high of $218.66, while it has fallen to a 52-week low of $163.81. The 50-Day Moving Average of the stock is -1.24%, while the 200-Day Moving Average is calculated to be -1.71%.
Shares Statistics:
It appears that ABBV traded 6.75M shares on average per day over the past three months and 6198020 shares per day over the past ten days. A total of 1.77B shares are outstanding, with a floating share count of 1.76B. Insiders hold about 0.09% of the company’s shares, while institutions hold 75.00% stake in the company. Shares short for ABBV as of 1749772800 were 14700538 with a Short Ratio of 2.36, compared to 1747267200 on 19929844. Therefore, it implies a Short% of Shares Outstanding of 14700538 and a Short% of Float of 0.83.
Dividends & Splits
With its trailing 12-month dividend rate of 6.38, ABBV has a forward annual dividend rate of 6.47. Against a Trailing Annual Dividend Yield of 0.03371024The stock’s 5-year Average Dividend Yield is 3.91.
